Translational Relevance
Therapeutic approaches that improve the dismal situation of patients suffering from advanced and aggressive thymic epithelial malignancies (TEMs) are missing since the molecular mechanisms involved in the establishment of this cancer are largely unknown. Here we demonstrate, by using newly established in vitro models, that Hsp90 is a critical and multimodal modifier of TEMs. Pharmacological inhibition of The hitherto disappointing results related to targeted therapies in this cancer might reflect the lack of representative model systems for preclinical studies, as well as the necessity to simultaneously block diverse oncogenic mechanisms in order to achieve potent anti-neoplastic activity in most tumors (4) . Regarding the first aspect, adequate mouse models that recapitulate this cancer are still missing but advancements have been made by establishing stable cell lines derived from TEMs (5, 6) . Regarding the second aspect, preliminary studies have shown beneficial effects of the multikinase inhibitors sorafenib and sunitinib in TEMs (7) . Besides the use of nonspecific multikinase inhibitors, specific mono-targeted inhibition of the molecular chaperone Hsp90 represents a compelling strategy that allows a synchronized blockade of multiple malignancy driving mechanisms (8) . Hsp90 generally regulates the stabilization and activation of so-called "client" proteins, numerous of which are bona fide oncoproteins (9) . Hence, Hsp90 controls signaling pathways involved in the establishment of all hallmarks of cancer (10) . Hsp90 inhibition induces the simultaneous proteasomal degradation of various onco-clients.
The therapeutic efficacy of Hsp90 inhibitors most likely relates to the concurrent shutdown of multiple pro-tumorigenic circuitries, hence preventing possible ''escape'' mechanisms of tumor cells by activating compensatory signaling pathways (10) .
Reports from clinical trials with the geldanamycin class of Hsp90 inhibitors (e.g. 17-AAG) demonstrate beneficial effects in several malignancies. However, this compound series has several limitations and an unfavorable toxicity profile (11, 12) .
With the advent of novel Hsp90 inhibitors that lack geldanamycin's benzoquinone moiety, which is deemed accountable for most of the observed side effects, hope has been raised that these compounds will improve the clinical applicability of Hsp90 inhibition (13) .
Here, we show that the Hsp90-sheltered activity of insulin-like growth factor 1 receptor (IGF-1R) contributes to the anti-apoptotic phenotype of thymic epithelial cancer cells. We demonstrate that IGF-1R overexpression manifests this newly identified mechanism of malignancy in advanced TEMs. Hsp90 inhibition reverses IGF-1R-mediated anti-apoptosis and induces multimodal anti-tumor activity. Our results suggest that Hsp90 inhibitors may represent promising therapeutic agents for the treatment of TEMs. 
Western Immunoblotting
Preparation of total protein lysates from human thymomas, thymic carcinomas, and normal thymi was performed as previously described (15) . Preparation of total protein lysates from cell cultures as well as subsequent SDS-PAGE and Western
Immunoblotting was performed as previously described (16) . See supplementary material for the antibodies employed.
Tissue microarray (TMA)
The tissue microarray was designed as previously described (15) . Matching clinical data of the tissue array subjects including Masaoka stage (17) are given in Table 1 .
Immunohistochemistry
Paraffin sections, each 4 μm thick, were cut, de-paraffinized in xylene and rehydrated with graded ethanol.
IGF-1R staining: 1 mM EDTA buffer (pH 9) was added to the slides and samples were heated by incubation in a microwave oven at 600 W for 3 x 5 min. After cooling, the slides were treated with hydrogen peroxidase in PBS to block the endogenous peroxidase. Nonspecific antibody-binding was blocked using the avidin/biotin The Hsp90 client IGF-1R represents a novel therapeutic target that contributes to apoptosis evasion in thymic cancer cells Given the lack of insight into molecular mechanism relevant to TEMs, we attempted to dissect the contribution of each of the investigated Hsp90 clients to the establishment of the malignant phenotype of TC1889 cells.
We first employed pharmacological inhibitors to independently block the function of the clients EGFR, IGF-1R, CDK4, RAF-1, and Akt (supplementary Table S1 ). In order to corroborate our pharmacologically-based strategy and to take liabilities like offtarget effects of the inhibitors into consideration, we further employed RNA interference (RNAi) to silence the highly druggable and hence clinically relevant clients IGF-1R, EGFR, and CDK4 (18) (19) (20) independently.
The different inhibitors employed reduced cell viability in a concentration-and timedependent manner with the IGF-1R inhibitor PPP being the most potent compound (IC50: ~0.25 μM Figure 2A) . Regarding EGFR inhibition, we also tested iressa/gefitinib, a drug previously tested in clinical trials with patients suffering from TEMs (3) and found that none of the gefitinib concentrations employed (up to 50 μM) were sufficient to achieve a half maximal reduction of cell viability (supplementary Figure S3 ). Since the efficacy of EGFR inhibitors can be associated with specific EGFR mutations (21), we tested whether these mutations can be found in TC1889 
were strongest for IGF-1R knockdown with a ~40 % decrease in viability for both siRNAs after 120 h ( Figure 2B ). Figure S4A and B) .
Given that
In order to strengthen our results that suggested an important role of the Hsp90 client IGF-1R and its potential to represent a valid therapeutic target in TEMs, we additionally analyzed the effects of a neutralizing IGF-1R antibody (αIR3) and of the IGF-1R inhibitors NVP-AEW541 (NVP) and BMS-536924 (BMS). Notably, all of these strategies to interfere with IGF-1R signaling reduced TC1889 cell viability and significantly induced apoptosis ( Figure 3A and B).
Related to IGF-1R inhibition-induced apoptosis, we also observed that inhibition of caspase-3, -8 and -9 reduced hypodiploidy associated with PPP treatment ( Figure   3C ). Additionally, PPP treatment induced mitochondrial depolarization ( Figure 3D 
IGF-1R is overexpressed in thymic tumors
Given the potential relevance of IGF-1R for the malignant anti-apoptotic phenotype of thymic epithelial tumor cells, we finally investigated whether these functional in vitro data are matched by expression data in human TEMs. Using Western immunoblot analyses, we initially found that IGF-1R expression in normal thymi samples was hardly detectable, whereas IGF-1R was expressed in the vast majority of TEMs (supplementary Figure S8) . In order to corroborate and extend this finding and to take into account that the results may have been confounded by the presence of lymphocytic infiltrates, particularly in normal thymi samples, we performed immunohistochemistry employing tissue micro arrays (TMA) ( Figure 5 and Table 1 ).
Considering IGF-1R expression in the epithelial compartment only, a low expression intensity of IGF-1R was observed in normal thymi ( Figure 5A, arrow) . Overall, a trend was observed for higher IGF-1R expression in TEMs as compared to normal thymi (p=0.0005) and significant differences were observed between normal thymi and thymic tumors (p=0.006). In direct comparison to normal thymi, a higher expression of IGF-1R was observed in type B2 (p=0.032), and type B3 thymoma (p=0.008), as well as thymic carcinoma (p=0.008). Statistical analyses also revealed that there were significant differences regarding IGF-1R expression and Masaoka stages (p=0.044), with advanced stages showing higher IGF-1R expression (see supplementary Table   S2 and S3). Additionally, an analysis of IGF-I expression ( Figure 5B and Table 1) revealed a trend towards higher expression in thymic carcinoma (p=0.012), however no statistically significant differences could be calculated when normal thymi were compared with TEMs. 
Discussion
Here, we dissected pro-tumorigenic mechanisms relevant to thymic epithelial malignancies (TEMs) and identified novel therapeutic targets. To our knowledge, this is the first functional analysis of factors relevant to TEMs that therefore differentiates itself from the descriptive nature of other studies, which are solely based on expression analyses by immunohistochemistry or global gene expression arrays, e.g. (23) (24) (25) . Importantly, we provide evidence that the molecular chaperone Hsp90 plays a vital role in the maintenance of the cancer phenotype of thymic epithelial tumor cells. We demonstrate that Hsp90 "safeguards" the stability and activity of multiple molecules, such as IGF-1R, CDK4, and EGFR, which we found to differentially contribute to the survival of thymic cancer cells. In this regard, Hsp90 may rather support malignancy by capacitating various pro-tumorigenic aberrations (8) , than act as a classical oncoprotein; a phenomenon referred to as "non-oncogene addiction" (26) . Consequently, inhibition of Hsp90 interferes with multiple malignancy driving mechanisms and elicits multimodal anti-neoplastic activity (11) . We show here that, in thymic cancer cells, this is reflected by the induction of cell cycle arrest and apoptosis, as well as the abrogation of invasiveness.
Given the observed anti-tumor potency of Hsp90 inhibition, alongside its known mechanism of onco-client degradation, we hypothesized that characterizing the protumorigenic role of specific Hsp90 clients in thymic carcinoma cells might enable us to obtain insights into the largely unknown mechanisms of malignancy in this cancer. 
TEMs (n=132) confirmed an overexpression of IGF-1R and found correlations with WHO classification, stage and relapse (27) . Interestingly, loss of heterozygosity in the 6q23.3-25.3 region, harboring amongst others IGF-2R, has been observed to be the most frequent chromosomal aberrations in TEMs (24) . Absence of IGF-2R, which sequesters IGF, might theoretically lead to locally increased IGF concentrations (28) .
Moreover, comprehensive genomic analyses revealed that IGF2BP3/IMP-3, a translational activator of IGF mRNA (29) , is highly overexpressed in thymic carcinomas (25) . Our initial analyses revealed that, although a trend towards higher IGF-I expression in thymic carcinoma could be observed, IGF-I was not statistically significantly overrepresented in TEMs when compared to normal thymi. Nevertheless, support that IGF-signaling might represent a potential oncogenic mechanism in TEMs stems from transgenic mice overexpressing either IGF-II or the IGF-binding protein 4 (IGFBP4). Whereas thymic size is markedly increased in the former mouse models (30, 31) , it is decreased in the latter, being associated with apoptosis (32) . 
Regarding other Hsp90 clients, our results support the notion that CDK4 contributes to thymic carcinoma cell survival. Correspondingly, previous reports have shown that inactivation of p16
INK4A
, which results in higher CDK4 activity (35) , is involved in the progression of TEMs (36) . Regarding EGFR, which is frequently overexpressed in TEMs (23) , mutations that alter its susceptibility towards different inhibitors are rare in this cancer (37) (38) (39) . Accordingly, we observed a rather poor performance of EGFR inhibitors in TC1889 cells, which do not harbor relevant EGFR mutations (data not shown). Further analyses are compulsory in order to reveal the actual importance of CDK4 and EGFR-signaling in the malignancy of TEMs.
Besides allowing an insight in pro-tumorigenic mechanisms of TEMs, our studies interestingly also revealed that mono-targeted inhibition of every onco-client alone, as exemplified by IGF-1R inhibition, can be associated with a prolonged activation of vital signaling cascades, e.g. MAPK/Erk-signaling. Off-target effects of the substances employed, as well as varying selectivity, e.g. the IGF-1R inhibitors NVP and BMS are known to also inhibit the insulin receptor (22) , might contribute to these effects. Given that certain inhibitors elicit differential effects depending on the respective genetic background of cancer cells (40) care has to be taken in interpreting our results related to signaling pathways modified by the substances used. Additional studies are mandatory to comprehensively address this topic. Still, activation of potentially compensatory signaling pathways as a consequence of targeted inhibition of one factor could generally be related to the plasticity and adaptability of signaling networks (41) . As previously demonstrated in other malignancies, these mechanisms can contribute to the occurrence of secondary resistance against single agent approaches (41) (42) (43) . Further analyses are warranted to delineate whether compensatory pathway activation as a means of acquired resistance also relates to our initial observations. 
